Brief Introduction – Johnson & Johnson
Johnson & Johnson is one of the world’s leading healthcare companies, operating in Innovative Medicine and Medical Technology (MedTech). The investment case is based on defensive demand in healthcare, strong cash flow generation, a broadly diversified product pipeline, attractive growth prospects in the MedTech segment, and an exceptionally solid balance sheet.
The company combines several growth engines under one roof:
- Innovative Medicines (Pharma)
- Medical Technology (MedTech)
- Leading position in oncology
- Strong franchises in immunology and neuroscience
- Innovations in the cardiovascular field
- Surgical and ophthalmological technologies
- Long-term dividend growth
- Balance Sheet Quality
Unlike many pure pharmaceutical companies, Johnson & Johnson benefits from unique diversification between medicines and medical technology. This significantly reduces dependence on individual products.
Johnson & Johnson
Analysis Result: 4 out of 5 MUMAKS
Rating
This analysis evaluates Johnson & Johnson according to the UMBRELLA strategy using the MUMAK method. The evaluation is carried out across five decision phases: Geopolitics, Industry, Fundamentals, Market Sentiment, and Technical Analysis.
Structure: Classification → Key Statement → Rationale → Conclusion
The goal is not to predict the future precisely. The goal is orientation. We contextualize facts, demonstrate causal relationships, and structure a comprehensible decision logic.
We explain – you decide.
Geopolitics
Classification
The geopolitical environment remains fundamentally supportive for Johnson & Johnson. Aging populations, rising healthcare expenditures, an increasing number of cancer cases, and growing demand for modern medical technology create long-term structural growth drivers.
Healthcare is increasingly viewed as critical infrastructure and enjoys high political priority worldwide.
Key Takeaway
Johnson & Johnson benefits from globally rising demand for healthcare services, demographic change, and continuously growing investments in innovative medicines and medical technologies.
Rationale
Aging populations ensure long-term demand
In developed economies, the proportion of older people is continuously increasing. This leads to growing demand for:
- Cancer therapies
- Cardiovascular treatments
- Orthopedic procedures
- Surgical technologies
- Ophthalmology and vision correction
Johnson & Johnson is excellently positioned in all these areas.
Oncology remains a central growth driver
Management has set the goal of becoming the world’s leading oncology company by 2030. Darzalex and Carvykti, in particular, are driving growth in the cancer sector.
Healthcare expenditures show high resilience
Even in economically challenging times, demand for medical care remains stable. This results in:
- Predictable revenues
- Recurring cash flows
- Defensive nature of the business model
Compared to cyclical industries, Johnson & Johnson thus offers significantly higher stability.
Regulatory risks persist
The pharmaceutical industry continues to face challenges:
- Drug price regulations
- Reimbursement pressure from healthcare systems
- Patent expirations
- Legal risks and litigation
Therefore, continuous innovation remains crucial for long-term success.
Conclusion
The geopolitical and demographic environment remains very positive in the long term. Aging societies and rising healthcare expenditures will support Johnson & Johnson’s growth for many years to come.
→ MUMAK.me rating Phase 1: positive = 1 MUMAK
Johnson & Johnson
Geopolitics Rating: positive
Industry
Assessment
The healthcare industry continues to be one of the most attractive long-term growth sectors worldwide.
Demand is particularly supported by the following factors:
- Aging populations
- Increase in chronic diseases
- Advances in biotechnology
- Growing adoption of modern medical technology
Key Takeaway
Johnson & Johnson is active in structurally growing healthcare markets and has exceptionally high visibility into future demand.
Rationale
Pharmaceutical innovation as a growth engine
The Innovative Medicine division particularly benefits from:
- Oncology
- Immunology
- Neuroscience
- Cardiovascular medicine
These areas are among the most dynamic segments of the global healthcare industry.
MedTech provides additional diversification
Unlike many competitors, Johnson & Johnson has a significant medical technology division.
Key growth drivers include:
- Cardiovascular systems
- Surgical technologies
- Electrophysiology
- Ophthalmology products
The combination of pharma and MedTech represents a significant competitive advantage.
Strong innovation pipeline
The company continuously invests in new therapies and technologies.
Key innovation areas include:
- New cancer treatments
- Neurological therapies
- Robotic surgery
- Cardiovascular innovations
Management describes the current product pipeline as one of the strongest in the company’s history.
Patent expirations as a challenge
As with all large pharmaceutical companies, risks arise from the loss of exclusive rights for existing medicines.
In particular, the expiration of important patents requires successful new product launches to offset revenue declines.
Conclusion
The healthcare industry remains structurally attractive. Johnson & Johnson benefits from unique diversification between pharma and medical technology and is simultaneously positioned in some of the fastest-growing healthcare segments.
→ MUMAK.me Evaluation Phase 2: positive = 1 MUMAK
Johnson & Johnson
Industry Rating: positive
Fundamentals
Assessment
Johnson & Johnson continues to exhibit the characteristics of a high-quality, defensive growth company. The company combines stable revenue growth, high profitability, strong cash flow generation, and a conservative balance sheet structure.
For fiscal year 2026, revenue is expected to be around $100.9 billion, compared to $94.2 billion in 2025. This represents growth of approximately 7.1%. EBITDA is projected to increase from $33.3 billion to $37.1 billion, while the EBIT margin is expected to improve from 32.2% to 33.3%.
Growth is primarily driven by the pharmaceutical portfolio, the medical technology business, and the continuous innovation pipeline.
Key Takeaway
Johnson & Johnson possesses strong and resilient fundamentals. Stable growth, high profitability, excellent cash flow generation, and a conservative balance sheet make the company one of the highest-quality healthcare corporations worldwide.
Rationale
Revenue growth remains stable
| Key Figure | Latest Result |
|---|---|
| Revenue Q1 2026 | $24.06 billion |
| YoY revenue growth | approx. +6% |
| Forecast for fiscal year 2026 | +3% to +4% organic growth |
| Main Growth Drivers | Innovative Medicine, Oncology, Immunology, Medical Technology |
Revenue growth continues to be stable. In the first quarter of 2026, Johnson & Johnson achieved revenues of approximately $24.06 billion, representing an increase of about 6% compared to the previous year.
Market analysts expect the group’s revenue to rise to over $107 billion by fiscal year 2027.
Profitability remains exceptionally high
| Key Figure | FY2024 | FY2025 |
|---|---|---|
| EBIT Margin | 25,5% | 28,0% |
| Net Margin | 15,8% | 28,5% |
| EBITDA Margin | 33,8% | 35,9% |
Johnson & Johnson continues to be one of the most profitable companies in the global healthcare sector.
EBITDA growth of more than 11% is expected for fiscal year 2026. At the same time, margins continue their positive trend. This underscores the company’s strong market position, high pricing power, and operational efficiency.
Cash flow generation remains excellent
| Key Figure | Value |
|---|---|
| Free Cash Flow FY’25 | $17.2 billion |
| FCF growth YoY | +7,2 % |
| FCF Margin FY'25 | 22,6 % |
| Operating Cash Flow FY'25 | $24.5 billion |
Johnson & Johnson continues to generate exceptionally strong cash flows.
The high quality of cash flow enables the company to continuously increase dividends, undertake strategic acquisitions, and simultaneously finance extensive investments in research and development.
Balance sheet remains extremely solid
| Key Figure | Latest Result |
|---|---|
| Cash and cash equivalents | $19.7 billion |
| Total Debt | $49.3 billion |
| Net Debt | $29.2 billion |
| Net Debt / EBITDA | 0.9x |
| Current Ratio | 1.2x |
Johnson & Johnson has one of the strongest balance sheets in the healthcare sector and continues to be one of the most creditworthy companies worldwide.
The solid financial position provides the group with significant financial flexibility to fund future growth initiatives, acquisitions, and investments in new therapies and medical technologies.
Capital allocation remains shareholder-friendly
| Key Figure | Current Result |
|---|---|
| Annual dividend per share | $5.20 |
| Dividend Yield | approx. 3.2% |
| Earnings per share FY2025 | $11.03 |
| EPS growth FY2025 | +90,5 % |
Dividend Aristocrat
Johnson & Johnson belongs to an exclusive group of companies that have increased their dividend for more than six decades without interruption.
Strengths for income investors:
- Over 60 years of continuous dividend increases
- Dividend comfortably covered by free cash flow
- Attractive yield combined with a defensive healthcare business
- Combination of current income, stability, and long-term wealth accumulation
Conclusion
Johnson & Johnson’s fundamentals remain strong.
The company continues to show solid and continuous revenue growth, while profitability is among the highest within the global healthcare industry. At the same time, strong cash flow generation and high financial stability provide significant strategic flexibility.
While litigation, regulatory risks, and expiring patents remain important factors that investors should monitor, the overall quality of the business model is not significantly affected.
Thanks to its strong market position, broad diversification, innovative product pipeline, and conservative financial policy, Johnson & Johnson remains one of the highest-quality companies in the global healthcare sector.
→ MUMAK.me Rating Phase 3: positive = 1 MUMAK
Johnson & Johnson
Fundamentals Rating: positive
News, Analysts, and Market Sentiment
Assessment
Johnson & Johnson currently benefits from positive market perception. This is supported by its defensive business model, strong balance sheet, diversified healthcare portfolio, and robust drug pipeline.
At the same time, patent expirations and ongoing legal proceedings remain important risk factors.
Key Takeaway
Market sentiment remains positive. However, future price development increasingly depends on whether new products can deliver the expected growth contributions.
Rationale
Analysts remain optimistic
| Number of Analysts | 24 |
| Average Price Target | ~$252 |
| Upside to Average Target | +8,6 % |
| Upper Target | ~$285 |
| Lower Target | ~$155 |
Detailed Distribution
| Revenue and Profit | |
|---|---|
| Buy | 10 |
| Accumulate | 5 |
| Hold | 8 |
| Reduce | 1 |
| Sell | 0 |
The majority of analysts continue to rate the stock positively.
The main reasons for this are:
- Strong market position
- High balance sheet quality
- Solid dividend growth
- Attractive product pipeline
The analyst consensus still indicates moderate price potential.
Product pipeline supports future growth
Particular attention is paid to the products:
- Darzalex
- Carvykti
- Tremfya
- Tecvayli
- Talvey
These medicines are expected to make a significant contribution to revenue growth in the future and compensate for expiring patent revenues.
Legal risks remain significant
The talcum powder lawsuits continue to represent the most significant uncertainty factor.
Although Johnson & Johnson has sufficient financial resources, legal developments can influence valuation and market sentiment in the short term.
Defensive characteristics remain in demand
During economically uncertain periods, investors prefer companies with:
- Stable earnings
- Solid balance sheets
- Predictable cash flows
- Reliable dividend growth
Johnson & Johnson meets all these criteria and therefore remains a core position for many institutional investors.
Conclusion
Overall, market sentiment towards Johnson & Johnson remains positive. Analysts continue to expect moderate upside potential. In the long term, the successful implementation of the pharmaceutical pipeline, growth in the MedTech sector, and the handling of legal risks will be decisive for further development.
→ MUMAK.me Evaluation Phase 4: positive = 1 MUMAK
Johnson & Johnson
Market Sentiment Rating: positive
Technical Analysis
Assessment
Technical analysis structures the timing framework of a position.
Johnson & Johnson’s technical structure has increasingly deteriorated in recent months. After a strong upward movement until early 2026, the stock is now in an extended consolidation and correction phase.
While Johnson & Johnson continues to benefit from its defensive market position, stable cash flows, and strong dividend history, the current chart structure signals weakness rather than trend strength in the short term.
The technical situation currently suggests a continuation of consolidation within a larger sideways phase rather than an immediate resumption of the long-term uptrend.
Key Takeaway
Johnson & Johnson is currently in a technically weaker market phase with declining momentum and a damaged trend structure.
The stock has so far defended important support levels, but currently shows neither sufficient trend strength nor a reliable signal for a new uptrend.
Rationale
Development in recent weeks/months
After the strong rise into the area of:
~$248.56
a longer sideways movement at a high level initially developed.
Since March, however, there has been:
- waning momentum
- increasing selling pressure
- series of lower highs
- lack of trend continuation
The stock repeatedly fell below important short-term support levels and is currently only just above the central support zone around:
~$219–220
The medium-term trend structure has thus significantly clouded.
Bollinger Bands
The stock traded in a stable uptrend along the upper Bollinger Band for an extended period.
After the high in the range of:
~$248.56
there was, however:
- successively falling highs
- declining trend dynamics
- increased downward volatility
- loss of institutional trend control
The current price is now near the lower Bollinger Band and clearly below the middle Bollinger Line.
This signals:
- weak buyer momentum
- dominant selling pressure
- lack of trend acceleration
- increased uncertainty
The Bollinger structure has thus developed from:
→ expansively bullish
to:
→ defensive and weak
developed.
RSI
The RSI recently fell significantly and is currently in the range of:
~39–40
This reflects:
- negative momentum
- lack of buyer momentum
- increasing market caution
- weak trend stability
The RSI is thus already approaching oversold areas.
This means:
- increased short-term counter-movements possible
- technical recovery conceivable
- but no confirmed trend reversal yet
The RSI currently signals:
→ weak market structure
with a lack of buyer dominance.
MACD
The MACD lines are again in negative territory and show increasing weakness.
This indicates:
- persistent downward momentum
- lack of trend acceleration
- declining buyer activity
- uncertainty about the further market phase
point to.
The MACD currently confirms the weaker market phase and has not yet provided a reliable buy signal.
Conclusion
From a chart perspective, the current pattern looks like:
→ Uptrend → Sideways phase → Loss of momentum → Correction
Johnson & Johnson is currently in a technically weaker market phase.
→ Several recovery attempts failed at resistance levels
→ Momentum indicators currently do not confirm a new upward wave
→ Buyer momentum remains limited
→ Trend structure appears damaged
The current technical setup currently points more toward:
→ Risk control and waiting
than toward:
→ aggressive position building.
→ MUMAK.me Evaluation Phase 5: negative = 0 MUMAK
Johnson & Johnson
Technical Analysis Evaluation: negative
Summary
The analysis shows an overall stable positive picture with an attractive long-term strategic positioning.
→ Geopolitics → Industry → Fundamental Data → Market Sentiment → Chart Analysis
Johnson & Johnson continues to be one of the world’s leading healthcare companies, combining defensive stability with innovation-driven growth.
The investment case is increasingly based on:
Innovative Medicine + Medical Technology (MedTech) + Oncology + Immunology + Cardiovascular Innovations + Surgical Technologies + Dividend Growth + Balance Sheet Strength
Johnson & Johnson benefits from:
- aging populations and rising healthcare expenditures
- strong market positions in oncology, immunology, and neuroscience
- a broadly diversified healthcare portfolio
- growing demand for modern medical technology
- high profitability and strong cash flow generation
- one of the strongest balance sheets in the healthcare sector
- continuous innovation through a strong product pipeline
- more than six decades of continuous dividend increases
Johnson & Johnson thus remains a high-quality healthcare company with attractive long-term growth prospects. The central risk factor lies less in operational development or financial strength, but primarily in patent expirations, regulatory risks, litigation, and the currently damaged chart technical situation.
Rating According to the MUMAK Method
| Category | Rating |
|---|---|
| Geopolitics | Positive |
| Industry | Positive |
| Fundamentals | Positive |
| News & Sentiment | Positive |
| Technical Analysis | Negative |
